Skip to main content

Advertisement

Log in

Complexes of technetium-99m with tetrapeptides containing one alanyl and three glycyl moieties

  • Original article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Recently, we have shown that tetrapeptides can be efficiently labelled with technetium-99m by direct labelling at alkaline pH. Tetrapeptides can be considered derivatives of mercaptoacetyltriglycine (MAG3) in which the mercaptoacetyl moiety is replaced by an amino acid residue. In view of the interesting biological properties of some C-methyl substituted derivatives of99mTc-MAG3, we have now synthesised and evaluated the complexes of99mTc with tetrapeptides containing three glycyl (G) moieties and oned- orl-alanyl (A) moiety. In mice,99mTc-l-GAGG,99mTc-d-GGAG and99mTc-l-GGAG showed a rapid and high renal excretion, comparable to that of99mTc-MAG3. Renal handling was somewhat reduced for isomersd andl of99mTc-AGGG and99mTc-d-GAGG and markedly inferior for99mTc-l-GGGA and99mTc-d-GGGA. In the baboon,99mTc-l-AGGG,99mTc-d-AGGG and99mTc-l-GAGG showed a comparable or even higher 1-h plasma clearance than99mTc-MAG3.99mTc-d-GAGG,99mTc-l-GGAG and99mTc-d-GGAG were characterised by a lower plasma clearance and the clearance of99mTc-l-GGGA and99mTc-d-GGGA was remarkably low. The three99mTc-labelled tetrapeptides with the highest plasma clearance in a baboon were compared with99mTc-MAG3 in a human volunteer.99mTc-l-AGGG and99mTc-l-GAGG had a roughly similar plasma clearance as99mTc-MAG3. The clearance of99mTc-d-AGGG was significantly lower and liver uptake was clearly visible with this compound. Left kidney renograms of99mTc-l-AGGG and99mTc-d-AGGG indicated moderate kidney accumulation. On the other hand, the renogram obtained after injection of99mTc-l-GAGG had an excellent shape and the maximum kidney concentration was slightly higher than for99mTc-MAG3. These results show the importance of the position of the methyl substituent on the99mTc-tetrapeptide with respect to its biological behaviour.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Fritzberg AR, Kasina S, Eshima D, Johnson DL. Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement.J Nucl Med 1986; 27: 111–116.

    PubMed  Google Scholar 

  2. Abdel-Dayem HM, Sadek S, al-Bahar R, Sabha M, el-Sayed M. Comparison of99Tcm-mercaptoacetyltriglycine and131I-orthoiodohippurate in determination of effective renal plasma flow (ERPF).Nucl Med Commun 1989; 10: 99–107.

    PubMed  Google Scholar 

  3. Lee H-B, Blaufox MD. Technetium-99m MAG-3 clearances after captopril in experimental renovascular hypertension.J Nucl Med 1989; 30: 666–671.

    PubMed  Google Scholar 

  4. Russell CD, Thorstad B, Yester MV, Stutzman M, Baker T, Dubovsky EV. Comparison of technetium-99m MAG3 with iodine-131 hippuran by a simultaneous dual channel technique.J Nucl Med 1988; 29: 1189–1193.

    PubMed  Google Scholar 

  5. Tubis M, Posnick E, Nordyke RA. Preparation and use of131I labeled sodium iodohippurate in kidney function tests.Proc Soc Exp Biol Med 1960; 103: 497–498.

    PubMed  Google Scholar 

  6. Schwartz FD, Madeloff MS. Simultaneous renal clearances of radiohippuran and PAH in man [abstract].Clin Res 1961; 9: 208.

    Google Scholar 

  7. Burbank MK, Tauxe WN, Moher F, Hunt JC. Evaluation of radioiodinated hippuran for the estimation of renal plasma flow.Proc Staff Meet Mayo Clin 1961; 36: 372–386.

    Google Scholar 

  8. Bubeck B, Brandau W, Dreikorn K, Sternbächer M, Eisenhut M, Trojan H, zum Winkel K. Clinical comparison of I-131o-iodohippurate with Tc-99m CO2-DADS-A and Tc-99m MAG3 by simultaneous double tracer measurement.Nuc Compact 1986; 17:135–138.

    Google Scholar 

  9. Vanbilloen H, Van Nerom C, Bormans G, Subhani M, De Roo M, Verbruggen A. Labelling of glycylalanyldiglycine with Tc-99m and study of biodistribution in mice.Eur J Nucl Med 1990; 16: 539.

    Google Scholar 

  10. Vanbilloen H, Bormans G, Heylen J, Hoogmartens M, De Roo M, Verbruggen A. Complexes of technetium-99m with tetraglycine and tetra-l-alanine and their biodistribution in mice.J Labelled Compd Radiopharm 1991; 30: 42–44

    Google Scholar 

  11. Bormans G, Vanbilloen H, Van Nerom C, Heylen J, Hoogmartens M, De Roo M, Verbruggen A. Complexes of technetium-99m with alanyltriglycine: labelling and biological characteristics of the respective isomers. In: Schmidt HAE, van der Schoot JB (eds)Nuclear medicine. The state of the art of nuclear medicine in Europe. Stuttgart New York: Schattauer, 1991: 121–123.

    Google Scholar 

  12. Vanbilloen HP, Bormans GM, De Roo MJ, Verbruggen AM. Complexes of technetium-99m with tetrapeptides, a new class of99mTc-labelled agents.Nucl Med Biol 1995; 22: 325–338.

    PubMed  Google Scholar 

  13. Bormans G, Cleynhens B, Hoogmartens M, De Roo M, Verbruggen A. Evaluation of99mTc-mercaptoacetyltripeptides in mice and baboon.Nucl Med Biol 1992; 19: 375–388.

    Google Scholar 

  14. Bormans GM, Cleynhens BJ, De Roo MJK, Verbruggen AM. Evaluation of the renal excretion characteristics of technetium-99m mercaptoacetylglycyl-d-alanylglycine in healthy volunteers.Eur J Nucl Med 1992; 19: 271–277.

    PubMed  Google Scholar 

  15. Greenstein JP, Winitz M.Chemistry of the amino acids. Malabar, Fl.: Krieger, 1984.

    Google Scholar 

  16. Verbruggen AM, Nosco DL, Van Nerom CG, Bormans GM, Adriaens PJ, De Roo MJ. Technetium-99m-l,l-ethylenedicysteine: a renal imaging agent. I. Labelling and evaluation in animals.J Nucl Med 1992; 33: 551–557.

    PubMed  Google Scholar 

  17. Vanbilloen H. Complexes of technetium-99m with derivatives of mercaptoacetyltriglycine. PhD Thesis, Leuven Faculty of Pharmaceutical Sciences, K.U. Leuven; 1994: 126–137.

  18. Bormans G, Gleynhens B, Adriaens P, De Roo M, Verbruggen A. Synthesis and labelling characteristics of99mTc-mercaptoacetyltripeptides.J. Labelled Compd Radiopharm 1993; 33: 1065–1078.

    Google Scholar 

  19. Verbruggen AM. Radiopharmaceuticals: state of the art.Eur J Nucl Med 1990; 17: 346–364.

    PubMed  Google Scholar 

  20. Despopoulos A. A definition of substrate specificity in renal transport of organic anions.J Theoret Biol 1965; 8: 163–192.

    Google Scholar 

  21. Bormans G, Cleynhens B, Hoogmartens M, De Roo M, Verbruggen A. Synthesis and biological evaluation of99mTc-mercaptoacetlyglycyl-l-alanyl-l-alanylglycine-B and99mTc-mercaptoacetlyglycyl-l-alanylglycine-B in mice and baboon.J Nucl Med All Sci 1989; 33: 275–276.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vanbilloen, H.P., De Roo, M.J. & Verbruggen, A.M. Complexes of technetium-99m with tetrapeptides containing one alanyl and three glycyl moieties. Eur J Nucl Med 23, 40–48 (1996). https://doi.org/10.1007/BF01736988

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01736988

Key words

Navigation